HIF-PHIs have several advantages including oral administration, physiological EPO
secretion, and improved iron utilization. Undoubtedly, HIF-PHIs will pave the new way in the …

Introduction The hypoxia-inducible factor prolyl hydroxylase (HIF-PH) pathway is
responsible for regulating the biosynthesis of erythropoietin (EPO) and maintaining iron …

Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising
new class of orally administered drugs currently in late-stage global clinical development for …

Anemia is a common feature and complication of chronic kidney disease (CKD).
Erythropoiesis-stimulating agents (ESAs) and recombinant human erythropoietin have been …

Introduction: In the last decade, concerns have been raised around the use of erythropoiesis-
stimulating agents (ESAs) and intravenous iron in chronic kidney disease (CKD) patients …

The objective was to provide a comprehensive summary of existing evidence on the efficacy
and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) for the …

Background: Anemia is one of the common complications of chronic kidney disease (CKD),
and its prevalence has been arising globally. The key cause of anemia in CKD patients is …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …

Background: Anemia is a common complication in CKD patients. Despite the use of iron and
erythropoietin-stimulating agents, the control rate of anemia in CKD is not satisfying. Novel …